Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Quarterly report, published

State of Peptides, 2026 Q3

47 of the 82 peptides we track are not FDA approved, and 40% of those have no randomized human trial. This report measures the peptide landscape from our open dataset of 82 peptides, 50 state records, and 31 cost records, plus public FDA adverse event data. Every figure is computed from the data you can download below.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.

Press releaseDownload the CSV data

What are the key findings?

  • 40%of the 47 tracked peptides without an FDA approval have no randomized human trial behind them (19 peptides).
  • 35 of 82tracked peptides are FDA approved. The most common status among the rest is "unscheduled" (15 peptides).
  • 52%of tracked peptides are prohibited in sport under the WADA list in force (43 of 82).
  • 13dated regulatory actions on tracked peptides in 2026 so far, 7 of them in the third quarter.
  • 34 of 94price channels in our cost data have a dated public source and a published price, covering 12 peptides.
  • 12,083 to 98,396sum of per-drug FAERS report counts for the FDA-approved GLP-1 and incretin peptides, 2016 versus 2025 (a report naming two of these drugs counts twice). Report counts are not incidence rates.
  • 29 of 50states allow a telehealth prescription without a live visit (asynchronous care); 7 do not, and in 14 the state law we checked does not settle it. In 15 of the 29, the law also says an online questionnaire alone is not enough.

1. Where does each peptide stand with regulators?

Each peptide record carries one United States regulatory status and one WADA status, both sourced on the peptide page. The status rules are defined on the methodology page.

United States regulatory status of tracked peptides35 of 82 tracked peptides (43%) are FDA approved and 47 are not. None is on the FDA 503A bulks list.
Show the data table
United States regulatory status of tracked peptides
StatusPeptidesShare
FDA approved3543%
503A bulks list00%
HHS interim policy (draft)67%
In FDA review (Category 1)34%
Nomination withdrawn1113%
Not eligible for compounding1113%
Unscheduled1518%
Former FDA approval (Geref)11%
Embed this chart
WADA status of tracked peptides43 of 82 tracked peptides (52%) are prohibited in sport under the WADA list in force.
Show the data table
WADA status of tracked peptides
WADA statusPeptidesShare
WADA prohibited4352%
Not WADA prohibited2834%
WADA status unclear1113%
Embed this chart

Compounding status of peptides without an FDA approval

Compounding status of peptides without an FDA approval
StatusPeptidesShare
503A bulks list00%
HHS interim policy (draft)613%
In FDA review (Category 1)36%
Nomination withdrawn1123%
Not eligible for compounding1123%
Unscheduled1532%
Former FDA approval (Geref)12%

Regulatory actions in 2026

13 dated actions affecting tracked peptides so far this year, 7 in the third quarter. Each links to its primary source; the full history is on the regulatory tracker.

  1. WADA

    WADA 2026 Prohibited List takes effect

    The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.

    Affects:TesamorelinSermorelinCJC-1295IpamorelinGHRP-2GHRP-6HexarelinMK-677 (ibutamoren)AOD-9604IGF-1 LR3PEG-MGFTB-500HCG (human chorionic gonadotropin)GonadorelinKisspeptin-10ACE-031 (ramatercept)InsulinDesmopressinBPC-157MOTS-c

  2. FDA

    FDA approves Imcivree (setmelanotide) for acquired hypothalamic obesity

    FDA extended Imcivree to acquired hypothalamic obesity in adults and children 4 years and older, based on the phase 3 TRANSCEND trial.

    Affects:Setmelanotide

  3. FDA

    FDA approves a 7.2 mg Wegovy dose for chronic weight management

    FDA approved a higher 7.2 mg dose of Wegovy (semaglutide) injection, marketed as Wegovy HD, for weight loss and long-term maintenance of weight loss in certain adults.

    Affects:Semaglutide

  4. FDA

    FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2

    FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.

    Affects:BPC-157AOD-9604CJC-1295DihexaDSIP (delta sleep-inducing peptide)EpitalonGHK-CuIpamorelinKPVLL-37Melanotan IIMOTS-cPEG-MGFSelankSemaxThymosin alpha-1TB-500

  5. FDA

    FDA proposes to keep semaglutide, tirzepatide and liraglutide off the 503B bulks list

    FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, after tentatively finding no clinical need for outsourcing facilities to compound them from bulk. The notice was published May 1, 2026, and the comment period was extended to July 30, 2026. The proposal was not final as of September 2026. It does not change the 503A rules for patient specific compounding.

    Affects:SemaglutideTirzepatideLiraglutide

  6. PCAC

    FDA advisory committee reviews six peptides; FDA's briefing recommends against listing

    At its July 23 to 24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, semax, and epitalon for the 503A bulks list. FDA's own briefing slides proposed not adding any of them. The committee voted in favor of listing all six, as HHS confirmed in its October 2026 peptide policy. The committee is advisory, and FDA proposed no rule, so none of the six was added to the 503A bulks list.

    Affects:BPC-157KPVTB-500MOTS-cSemaxEpitalon

  7. PCAC

    FDA advisory committee reviews DSIP; FDA's briefing recommends against listing

    At the July 24, 2026 meeting, FDA presented delta sleep-inducing peptide (DSIP, emideltide) to its Pharmacy Compounding Advisory Committee and proposed not adding it to the 503A bulks list, citing poor characterization, insufficient safety data, immunogenicity concerns, and lack of evidence of effectiveness. FDA has not posted the vote or minutes. Its nomination was withdrawn, so it remains outside FDA's interim policy.

    Affects:DSIP (delta sleep-inducing peptide)

  8. Other

    Louisiana Act 374 on peptide compounding takes effect

    Louisiana Act 374 of 2026 (Senate Bill 253, La. R.S. 37:23.5), signed May 22, 2026, took effect August 1, 2026. It bars Louisiana licensing boards from prohibiting prescribers from providing peptides made by 503A pharmacies or 503B outsourcing facilities that comply with federal compounding law, and from prohibiting Louisiana pharmacists from compounding peptides in compliance with section 503A. It does not make any peptide eligible for 503A or 503B compounding.

  9. State board

    Mississippi medical, nursing, and pharmacy boards bar research-grade peptides

    The Mississippi State Board of Medical Licensure, Board of Nursing, and Board of Pharmacy jointly stated that no healthcare provider may compound, administer, dispense, prescribe, advise on, recommend, or supply a non-FDA-approved or research-grade peptide, that consent forms do not remove liability, and that all prescription products and ingredients must come from Board of Pharmacy permitted entities.

  10. FDA

    FDA approves Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes

    FDA added an indication for Mounjaro to lower the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events. The approval rests on SURPASS-CVOT, in which tirzepatide was non-inferior to dulaglutide (hazard ratio 0.92, 95.3% CI 0.83 to 1.01) but did not show superiority.

    Affects:Tirzepatide

  11. FDA

    FDA warning letter treats GLP-1 plus vitamin combinations as essentially copies

    In a warning letter dated September 18, 2026 and posted September 22, FDA said compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin (vitamin B12) appeared to be essentially copies of approved drugs, that the volume produced suggested the claimed differences were a pretext, and that significant-difference statements were repeated verbatim across many records or chosen from preset menus on prescribing platforms. The letter's findings are specific to one pharmacy, but they apply FDA's April 1, 2026 policy that a combination within 10% of approved strengths by the same route may be treated as essentially a copy without a documented prescriber determination.

    Affects:SemaglutideTirzepatide

  12. WADA

    WADA publishes the 2027 Prohibited List

    WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.

    Affects:TesamorelinSermorelinCJC-1295IpamorelinGHRP-2GHRP-6HexarelinMK-677 (ibutamoren)AOD-9604IGF-1 LR3PEG-MGFTB-500HCG (human chorionic gonadotropin)GonadorelinKisspeptin-10ACE-031 (ramatercept)InsulinDesmopressinBPC-157MOTS-c

  13. HHS

    HHS draft policy lets licensed pharmacies compound six peptides without enforcement action

    HHS Secretary Robert F. Kennedy Jr. announced a draft enforcement discretion policy (FR Doc. 2026-22192, filed October 28 and published in the Federal Register on October 30, 2026). HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157, epitalon, KPV, MOTS-c, semax, or TB-500, if the product contains a single active ingredient, uses an allowed route, is made from an FDA-registered manufacturer's substance with a tested certificate of analysis, carries a patient-specific prescription, and serious adverse events are reported to FDA. It is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Comments are open through November 13, 2026 on Docket HHS-OASH-2026-0496.

    Affects:BPC-157EpitalonKPVMOTS-cSemaxTB-500

2. How strong is the evidence, by cluster?

Each peptide's evidence grade, defined on the methodology page, is cited to its studies on the peptide page. Across all 82 peptides, 19 (23%) have no randomized human trial. Among the 47 peptides without an FDA approval, 19 (40%) have no randomized human trial.

Evidence grade by peptide cluster63 of 82 tracked peptides (77%) have randomized human trial evidence. Among the 47 without an FDA approval, 19 (40%) have no randomized human trial.
  • Human RCT evidence
  • Human observational evidence
  • Animal-only evidence
  • Anecdotal evidence only
  • No published evidence
Show the data table
Evidence grade by peptide cluster
ClusterHuman RCT evidenceHuman observational evidenceAnimal-only evidenceAnecdotal evidence onlyNo published evidenceTotal
Other peptides20000020
Metabolic and growth hormone axis13030016
GLP-1 and incretin agonists900009
Tissue repair and healing306009
Longevity and mitochondrial513009
Cognitive and neuroprotective223007
Sexual health and reproductive700007
Immune and antimicrobial401005
Embed this chart

3. What do peptides cost in cash?

The index includes only cost channels with a dated public source: a manufacturer list or self-pay price, a published cash price, a peer-reviewed price study, or a licensed provider's published price, each with the date it was checked. Of 94 channels across 31 cost records, 34 qualify. Estimates without a dated source are left out rather than averaged in. Channel detail is on each cost page, and GLP-1 prices are compared side by side on the GLP-1 hub.

Published monthly cash prices by channel34 of 94 price channels in the cost data (12 peptides) have a dated public source and a published price. 9 more were checked and no dated lawful price was found; 51 have no dated source yet and are left out.

Dots mark the low and high of each published range; a single dot is a single published figure. Prices per dose, vial, or pen are in the table only, since they are not comparable to monthly prices.

Show the data table
Price channels with a dated public source
PeptideChannelPrice (USD)UnitChecked onSources
DulaglutideSelf-pay through the manufacturer pharmacyfrom $389per month2026-09-27[1]
DulaglutideList price (Trulicity)$1,007per month2026-09-27[1] [2]
DulaglutideWith insurance$0 to $25per month2026-09-27[1] [2]
GlutathioneTelehealth program$75 to $100per month2026-09-22[1] [2] [3] [4]
GlutathioneIn-person clinic$35 to $50per dose2026-09-22[1] [2]
GonadorelinTelehealth program$50per vial2026-09-22[1] [2] [3]
LiraglutideGeneric cash price$112 to $924per month2026-09-22[1] [2] [3]
LiraglutideList price for type 2 diabetes$544 to $815per month2026-09-22[1] [2]
LiraglutideList price for weight management$1,349per month2026-09-22[1] [2] [3]
LiraglutideWith insurancefrom $25per month2026-09-22[1] [2] [3]
NAD+Telehealth program$79 to $199per month2026-09-22[1] [2] [3]
NAD+In-person clinic$400 to $900per dose2026-09-22[1] [2]
OxytocinBranded, from a pharmacy$2 to $4per vial2026-09-22[1] [2] [3]
OxytocinTelehealth program$115 to $135per month2026-09-22[1] [2] [3] [4]
PT-141 (bremelanotide)Branded, from a pharmacy$233 to $239per dose2026-09-22[1] [2]
PT-141 (bremelanotide)Telehealth program$187 to $224per month2026-09-22[1] [2]
PT-141 (bremelanotide)With insurance$0 to $25per dose2026-09-22[1] [2]
SemaglutideSelf-pay Wegovy and Ozempic$149 to $499per month2026-09-22[1] [2] [3] [4]
SemaglutideList price (Wegovy, Ozempic, Rybelsus)$1,028 to $1,349per month2026-09-22[1] [2] [3] [4]
SemaglutideCompounded pharmacy (2024 survey)$189 to $294per month2026-09-22[1] [2] [3] [4] [5]
SemaglutideTelehealth program$223 to $548per month2026-09-22[1] [2]
SemaglutideSavings offer for Wegovy with commercial insurancefrom $25per month2026-09-22[1] [2] [3]
SemaglutideMedicare GLP-1 Bridge$50per month2026-09-22[1] [2] [3]
SermorelinTelehealth program$105 to $180per month2026-09-22[1] [2] [3]
TeriparatideGeneric cash price$1,036 to $3,214per pen2026-09-22[1] [2] [3]
TeriparatideList price$4,290per pen2026-09-22[1] [2]
TeriparatideWith insurancefrom $4per month2026-09-22[1] [2]
TesamorelinBranded, from a pharmacy$10,709per month2026-09-22[1] [2] [3] [4]
TirzepatideSelf-pay Zepbound vials and KwikPen$299 to $699per month2026-09-22[1] [2] [3]
TirzepatideList price (Zepbound and Mounjaro)$499 to $1,112per month2026-09-22[1] [2]
TirzepatideCompounded pharmacy (2024 survey)$275 to $399per month2026-09-22[1] [2] [3] [4] [5]
TirzepatideTelehealth program$373 to $598per month2026-09-22[1] [2]
TirzepatideSavings card for Zepbound with commercial insurancefrom $25per month2026-09-22[1] [2] [3] [4]
TirzepatideMedicare GLP-1 Bridge$50per month2026-09-22[1] [2]
Embed this chart
Monthly price summary by channel, dated sources only
ChannelChannelsMedian lowMedian highLowestHighest
Branded, from a pharmacy10$521$1,007$112$10,709
Compounded pharmacy2$232$347$189$399
Telehealth program7$115$199$75$598
With insurance7$25$50$0$50

Monthly prices only. Medians use each channel's published low and high separately; a channel with only a floor (such as an insurance copay "as low as") contributes a low only.

4. What do FDA adverse event reports show?

We counted reports in the FDA Adverse Event Reporting System (FAERS, now part of the FDA Adverse Event Monitoring System [2]) that name each of the 35 FDA-approved peptides in the dataset, by the year FDA received them, through the public openFDA API. 34 of them have at least one report; 1 has none in openFDA. The pull ran on 2026-09-22; openFDA data was last updated 2026-07-30.

Read these counts with care. FDA states that a report does not establish that the product caused the event, that reports are not verified, that not every event is reported and many factors influence whether one is, and that the data cannot be used to estimate incidence. [1] So a rise in reports can reflect wider use or more reporting rather than more harm. A report counts here if the peptide appears anywhere in its drug list, as a suspect or a concomitant drug, and one report can list several reactions. The GLP-1 totals in the key findings and the chart below add up each drug's own report count, so a report naming two of these drugs counts twice. Approvals, prices, and state access for these drugs are on the GLP-1 hub.

FAERS reports per year naming a GLP-1 or incretin peptideThe sum of per-drug FAERS report counts for the FDA-approved GLP-1 and incretin peptides went from 12,083 received in 2016 to 98,396 in 2025 (a report naming two of these drugs counts twice). Many factors besides harm influence whether an event is reported, so counts are not rates.

Tirzepatide160,934 total

Tirzepatide: FAERS reports per year, 2016 5, 2017 7, 2018 4, 2019 27, 2020 33, 2021 35, 2022 5052, 2023 20809, 2024 33080, 2025 62395, 2026 to date 3948662k20162026 to date

Semaglutide100,912 total

Semaglutide: FAERS reports per year, 2016 20, 2017 21, 2018 1168, 2019 1834, 2020 3965, 2021 5526, 2022 8097, 2023 11908, 2024 19203, 2025 27550, 2026 to date 2160628k20162026 to date

Dulaglutide88,461 total

Dulaglutide: FAERS reports per year, 2016 3897, 2017 6243, 2018 7446, 2019 9365, 2020 10746, 2021 12654, 2022 11182, 2023 9545, 2024 7304, 2025 5898, 2026 to date 248313k20162026 to date

Exenatide84,435 total

Exenatide: FAERS reports per year, 2016 3440, 2017 3696, 2018 3857, 2019 4329, 2020 4241, 2021 2984, 2022 1827, 2023 1317, 2024 1219, 2025 335, 2026 to date 244.3k20162026 to date

Liraglutide53,485 total

Liraglutide: FAERS reports per year, 2016 4721, 2017 3609, 2018 4715, 2019 3278, 2020 2916, 2021 2533, 2022 2047, 2023 2076, 2024 1856, 2025 2218, 2026 to date 12984.7k20162026 to date

Each panel has its own scale. 2026 is partial (lighter bar): openFDA data last updated 2026-07-30. Pulled from openFDA on 2026-09-22.

Show the data table
FAERS reports per year naming a GLP-1 or incretin peptide
Peptide20162017201820192020202120222023202420252026 to dateAll years
Tirzepatide5742733355,05220,80933,08062,39539,486160,934
Semaglutide20211,1681,8343,9655,5268,09711,90819,20327,55021,606100,912
Dulaglutide3,8976,2437,4469,36510,74612,65411,1829,5457,3045,8982,48388,461
Exenatide3,4403,6963,8574,3294,2412,9841,8271,3171,2193352484,435
Liraglutide4,7213,6094,7153,2782,9162,5332,0472,0761,8562,2181,29853,485
Embed this chart
FAERS reports for every FDA-approved peptide in the dataset
Peptide20252026 to dateAll years in openFDAMost reported reaction
Insulin33,84915,574516,830blood glucose increased (86,382)
Tirzepatide62,39539,486160,934incorrect dose administered (29,676)
Teriparatide2,121800112,545nausea (9,039)
Semaglutide27,55021,606100,912nausea (14,475)
Leuprolide7,4882,18592,991hot flush (11,166)
Dulaglutide5,8982,48388,461nausea (10,444)
Exenatide3352484,435blood glucose increased (18,570)
Liraglutide2,2181,29853,485nausea (7,778)
Octreotide1,22958835,427diarrhoea (5,228)
Abaloparatide6,3184,56129,291headache (5,125)
Linaclotide2,4801,46527,604diarrhoea (5,075)
Lanreotide1,06042711,978diarrhoea (2,066)
Desmopressin5052418,649hyponatraemia (841)
Triptorelin8594207,246off label use (590)
Degarelix5822515,879fatigue (436)
Calcitonin220825,627drug ineffective (593)
Vasopressin5152204,741drug ineffective (1,367)
Glucagon4261614,553drug ineffective (399)
Enfuvirtide76353,750depression (555)
Tesamorelin2401473,517product dose omission issue (299)
HCG (human chorionic gonadotropin)1751053,388ovarian hyperstimulation syndrome (809)
Oxytocin186843,229foetal exposure during pregnancy (460)
Pramlintide2253,069blood glucose increased (951)
Ziconotide98412,716pain (389)
Ganirelix123621,930ovarian hyperstimulation syndrome (393)
Vosoritide4722061,331injection site pain (179)
PT-141 (bremelanotide)3422051,005nausea (432)
Cetrorelix3523736ovarian hyperstimulation syndrome (170)
GonadorelinReports mostly name gonadorelin as a GnRH analogue in cancer regimens (most often listed alongside breast and prostate cancer drugs); approved gonadorelin products are discontinued, so these counts do not describe the gonadorelin product.10423612neutropenia (96)
Terlipressin5540346drug ineffective (41)
Cosyntropin1611277foetal growth restriction (24)
Setmelanotide13340270nausea (77)
Melanotan I (afamelanotide)5119anaphylactic reaction (4)
Secretin0016pancreatitis acute (4)
SS-31 (elamipretide)000None reported

Each peptide name links to the exact openFDA query behind its count. Reaction terms are MedDRA preferred terms as reported. Every per-year query URL is in the CSV download.

5. Where can you get a peptide prescription by telehealth?

From our 50 state records, each citing the state's own statute or board rule. Telehealth prescribing is allowed in 50 states. Compounded GLP-1 access by state: limited in 50. 49 state records follow the FDA 503A bulks framework, 1 does not, and 0 are not addressed. The detail for each state is on its legal access page.

Asynchronous telehealth prescribing by stateTelehealth prescribing is allowed in 50 of 50 states. 29 allow a prescription without a live visit (asynchronous care), 7 do not, and in 14 the state law we checked does not settle it. In 15 of the 29, the law also says an online questionnaire alone is not enough.
  • Allowed
  • Not allowed
  • Not addressed in state rules
Asynchronous telehealth prescribing by stateTelehealth prescribing is allowed in 50 of 50 states. 29 allow a prescription without a live visit (asynchronous care), 7 do not, and in 14 the state law we checked does not settle it. In 15 of the 29, the law also says an online questionnaire alone is not enough.Alabama: AllowedALYesAlaska: Not addressed in state rulesAKn/aArizona: AllowedAZYesArkansas: Not allowedARNoCalifornia: AllowedCAYesColorado: AllowedCOYesConnecticut: AllowedCTYesDelaware: AllowedDEYesFlorida: AllowedFLYesGeorgia: Not allowedGANoHawaii: AllowedHIYesIdaho: AllowedIDYesIllinois: Not addressed in state rulesILn/aIndiana: Not addressed in state rulesINn/aIowa: AllowedIAYesKansas: Not addressed in state rulesKSn/aKentucky: Not addressed in state rulesKYn/aLouisiana: Not allowedLANoMaine: AllowedMEYesMaryland: AllowedMDYesMassachusetts: AllowedMAYesMichigan: AllowedMIYesMinnesota: Not addressed in state rulesMNn/aMississippi: Not allowedMSNoMissouri: Not addressed in state rulesMOn/aMontana: AllowedMTYesNebraska: AllowedNEYesNevada: AllowedNVYesNew Hampshire: AllowedNHYesNew Jersey: AllowedNJYesNew Mexico: Not allowedNMNoNew York: Not addressed in state rulesNYn/aNorth Carolina: AllowedNCYesNorth Dakota: AllowedNDYesOhio: AllowedOHYesOklahoma: Not addressed in state rulesOKn/aOregon: AllowedORYesPennsylvania: Not addressed in state rulesPAn/aRhode Island: Not allowedRINoSouth Carolina: Not addressed in state rulesSCn/aSouth Dakota: Not addressed in state rulesSDn/aTennessee: AllowedTNYesTexas: AllowedTXYesUtah: Not addressed in state rulesUTn/aVermont: AllowedVTYesVirginia: AllowedVAYesWashington: AllowedWAYesWest Virginia: Not allowedWVNoWisconsin: AllowedWIYesWyoming: Not addressed in state rulesWYn/a

Each tile links to that state's access page with the statute or rule cited.

Show the data table
State telehealth and compounding access
StateTelehealth prescribingAsynchronous prescribingCompounded GLP-1 accessFollows FDA 503A bulks
AlabamaAllowedAllowedLimitedYes
AlaskaAllowedNot addressedLimitedYes
ArizonaAllowedAllowedLimitedYes
ArkansasAllowedNot allowedLimitedYes
CaliforniaAllowedAllowedLimitedYes
ColoradoAllowedAllowedLimitedYes
ConnecticutAllowedAllowedLimitedYes
DelawareAllowedAllowedLimitedYes
FloridaAllowedAllowedLimitedYes
GeorgiaAllowedNot allowedLimitedYes
HawaiiAllowedAllowedLimitedYes
IdahoAllowedAllowedLimitedYes
IllinoisAllowedNot addressedLimitedYes
IndianaAllowedNot addressedLimitedYes
IowaAllowedAllowedLimitedYes
KansasAllowedNot addressedLimitedYes
KentuckyAllowedNot addressedLimitedYes
LouisianaAllowedNot allowedLimitedYes
MaineAllowedAllowedLimitedYes
MarylandAllowedAllowedLimitedYes
MassachusettsAllowedAllowedLimitedYes
MichiganAllowedAllowedLimitedYes
MinnesotaAllowedNot addressedLimitedYes
MississippiAllowedNot allowedLimitedYes
MissouriAllowedNot addressedLimitedYes
MontanaAllowedAllowedLimitedYes
NebraskaAllowedAllowedLimitedYes
NevadaAllowedAllowedLimitedYes
New HampshireAllowedAllowedLimitedYes
New JerseyAllowedAllowedLimitedYes
New MexicoAllowedNot allowedLimitedYes
New YorkAllowedNot addressedLimitedYes
North CarolinaAllowedAllowedLimitedYes
North DakotaAllowedAllowedLimitedYes
OhioAllowedAllowedLimitedYes
OklahomaAllowedNot addressedLimitedYes
OregonAllowedAllowedLimitedYes
PennsylvaniaAllowedNot addressedLimitedYes
Rhode IslandAllowedNot allowedLimitedYes
South CarolinaAllowedNot addressedLimitedYes
South DakotaAllowedNot addressedLimitedYes
TennesseeAllowedAllowedLimitedYes
TexasAllowedAllowedLimitedYes
UtahAllowedNot addressedLimitedYes
VermontAllowedAllowedLimitedYes
VirginiaAllowedAllowedLimitedNo
WashingtonAllowedAllowedLimitedYes
West VirginiaAllowedNot allowedLimitedYes
WisconsinAllowedAllowedLimitedYes
WyomingAllowedNot addressedLimitedYes
Embed this chart

6. What is still in preparation?

Two parts of the planned report need data we do not yet license, so they are not published and no figures are estimated in their place.

  • Search demand by peptide. In preparation. Method: monthly relative search interest for each peptide name and its common aliases, from a licensed search trend source, indexed to each peptide's own 12-month peak and reported as trends, not volumes.
  • Consumer survey. In preparation. Method: at least 1,000 United States adults, quota sampled by age, sex, and region through a licensed research panel, on peptide use, sourcing, and attitudes, with the full questionnaire, weighting, and margin of error published alongside the results.

7. Download the data

Every chart and table above is built from these files, licensed CC BY 4.0. Credit "PeptideAgent, State of Peptides, 2026 Q3" with a link to this page.

Report CSV downloads
FileContentsRows
regulatory-scorecard.csvCounts and shares of tracked peptides by United States regulatory status, compounding status (peptides without an FDA approval), and WADA status.18
regulatory-events-2026.csvDated FDA, PCAC, Federal Register, WADA, and state actions in 2026 affecting tracked peptides, with the primary source URL.13
evidence-by-cluster.csvNumber of tracked peptides in each cluster at each evidence grade.8
price-index.csvEvery cost channel with a dated source and a published price, in United States dollars, with the date checked and source URLs.34
faers-reports-by-year.csvopenFDA adverse event report counts by receipt year for each FDA-approved peptide, with the exact query URL for every count.385
faers-top-reactions.csvThe ten most frequently reported reaction terms (MedDRA preferred terms) per FDA-approved peptide, all years, with the query URL.340
state-access.csvTelehealth, asynchronous prescribing, compounded GLP-1 access, and 503A bulks alignment for all 50 states, with the pharmacy board.50

8. How was this made?

  • Regulatory, WADA, and evidence figures count the 82 peptide records in the dataset. Every record is editorially reviewed (not clinically reviewed), and each status cites its primary source on the peptide page.
  • The price index counts a channel only when the record gives the date the price was checked, at least one price, and sources that resolve to URLs. The latest check date in the index is 2026-09-27.
  • FAERS counts come from a script that queries the openFDA drug event endpoint once per peptide and year, searching the generic name and the United States product names of its approved products, and writes every query URL to a committed file.
  • State access figures count the 50 state records; a state where the rules we checked are silent is reported as not addressed, never guessed.
  • Figures recompute from the dataset on every deploy, so this page and the CSV files always agree. Corrections: press@peptideagent.ai.

Sources

  1. [1]openFDA drug adverse event API: endpoint documentation, coverage, and data limitationsFDA
  2. [2]FDA Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS)FDA, 2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, November 1). State of Peptides, 2026 Q3. https://peptideagent.ai/data/state-of-peptides-2026-q3
HTML link
<a href="https://peptideagent.ai/data/state-of-peptides-2026-q3">State of Peptides, 2026 Q3</a>, PeptideAgent, updated November 1, 2026.

Educational reference, not medical advice. Read the full disclaimer and talk to a licensed provider before starting, stopping, or combining any treatment.